Christian Simon

In this session, we delve into the innovative partnership between Sanofi and Saudi biopharmaceutical companies. This case study explores how their collaboration is advancing Saudi Arabia’s insulin localization strategy and contributing to the nation’s Vision 2030 goals. The discussion will focus on the strategic Memorandum of Understanding that Sanofi and Sudair have signed, enabling technology transfer, skill development, and the establishment of state-of-the-art manufacturing facilities in Saudi Arabia.

 Key Discussion Points:

• Technology Transfer and Workforce Development: Explore how Sanofi and Sudair are facilitating knowledge sharing and technology transfer to build a skilled biopharma workforce.
• Building Biopharmaceutical Capacity in Saudi Arabia: Learn how establishing cGMP-compliant manufacturing capabilities ensures reliable and high-quality insulin production for local markets.
•  Impact on Public Health and National Resilience: Understand the broader implications of this partnership on public health, including improved insulin accessibility, reduced pharmaceutical imports, and enhanced national preparedness for health emergencies.